Economic incentives to support EU companies moving away from hazardous chemicals could stimulate the transition of the market towards sustainability. This is the case that is presented in the latest ChemSec report, Unlock the market – Economic incentives for alternatives to hazardous chemicals.
From 1 July 2024, all rechargeable industrial and EV batteries will require a carbon footprint declaration, which will eventually transition into a mandatory maximum lifecycle carbon footprint threshold.
Medical hydrogels currently dominate hydrogel publicity, patents and research but others will become a larger business 2022 to 2042.* Self-healing and membrane hydrogels turn out to be extremely important for the future. Hydrogels can be tailored to be phase changing, shape memory, toxin and rare metal-grabbing and so much more. The properties can be useful in the new structural electronics and many types of sensors.
Nature has long inspired a range of technologies, like the shape of bullet trains and LED pixels, based on a kingfisher’s beak and the patterning on a butterfly wing, respectively. Now, however, biomimicry is being taken to new heights as natural degradation processes are being supercharged to tackle modern day waste.
Unfortunately, the EU and UK are still lagging behind in under-standing the difference between chemical pesticides and biopesticides, and they treat both types of products similarly.
In the last decade, many chemical process plants have been decommissioned having reached the end of their useful life. Many companies contract out the task to specialist companies. While so much has been written about operational safety and legislated for, decommissioning safety has not received much attention, except in the nuclear field and offshore oil & gas.
The Glasgow Climate Pact agreed at COP26 in November 2021 represents the most ambitious commitment yet to tackling human-caused climate change. Plastics will doubtless play a positive role in facilitating new technologies to meet those commitments.
Chemicals companies need to digitalise to be competitive, but many struggle to realise the full potential of what digital transformation could achieve for their business. A recent global study confirmed that only 19% of chemicals companies demonstrate real leadership in digital, with 45% ‘adopters’ still climbing the digital maturity curve and over a third (36%) ‘followers’, still in the early stages of digitalisation.
Advances in cell and gene therapies have happened at an exponential rate. Since Novartis broke open the market in 2017 with Kymriah – a gene therapy for blood cancer – the sector is booming and unlikely to slow down. More than 2600 trials are ongoing worldwide and the US FDA predicts it will be approving up to 20 therapies a year by 2025. Meanwhile, financing of regenerative medicine has soared.
Much emphasis is put on electric vehicle (EV) battery cells – and rightly so. However, EVs present a range of other opportunities. Cells are assembled into a pack containing a plethora of materials and components, including thermal interface materials (TIMs), fire safety, enclosures, insulation and compression foams.